Aktie 6919 CALIWAY BIOPHARMACEUTICALS CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Caliway Biopharmaceuticals Co., Ltd.

Aktien

6919

TW0006919004

6919

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 17.05.2024 		% 5 Tage % 1. Jan.
377 TWD -0,79 % Intraday Chart für Caliway Biopharmaceuticals Co., Ltd. -0,53 % +97,12 %
25.04. Caliway Biopharmaceuticals Co, Ltd. gibt bekannt, dass die Phase-2-Studie CBL-514 zur Behandlung von Cellulite alle primären und sekundären Endpunkte erreicht hat CI
04.03. Caliway Biopharmaceuticals Co, Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints
Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
Caliway Biopharmaceuticals Gets US FDA Nod for Phase 2 Trial of Dercum's Disease Drug
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease
Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study
Caliway Biopharmaceuticals Completes Recruitment for Severe Cellulite Drug Study
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
Caliway Biopharmaceuticals Co., Ltd.(TPEX:6919) added to S&P Global BMI Index
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 6919 Aktie
  4. Nachrichten Caliway Biopharmaceuticals Co., Ltd.
  5. Andere Sprachen